Alzheimer Disease

Modified alpha 2-macroglobulin inhibits A-beta cytotoxicity

Published in Vaccine Weekly, May 18th, 2005

A chemically modified preparation of alpha 2-macroglobulin binds beta-amyloid peptide with increased affinity and inhibits A-beta cytotoxicity.

According to a study from the United States, "Macromolecules that bind beta-amyloid peptide (A-beta) and neutralize A-beta cytotoxicity offer a promising new approach for treating Alzheimer disease. When the plasma protein, alpha 2-macroglobulin (alpha 2M), is treated with methylamine (alpha 2M-MA), it undergoes conformational change and acquires A-beta-binding activity. In this study, we demonstrate that a chemically stabilized preparation of human alpha 2M conformational intermediates (alpha 2M-cis-Pt/MA) binds A-beta with...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2005-05-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry